Elsevier

Regulatory Peptides

Volume 104, Issues 1–3, 15 March 2002, Pages 153-159
Regulatory Peptides

Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice

https://doi.org/10.1016/S0167-0115(01)00358-5Get rights and content

Abstract

A single dose of the orexin-1 (OX1) receptor antagonist 1-(2-methylbenzoxazol-6-yl)-3-[1,5] naphthyridin-4-yl urea hydrochloride (SB-334867-A) reduces orexin-A-induced feeding and natural feeding in Sprague Dawley rats. In this study, the anti-obesity effects of SB-334867-A were determined in genetically obese (ob/ob) mice dosed with SB-334867-A (30 mg/kg, i.p.) once daily for 7 days, and then twice daily for a further 7 days. SB-334867-A reduced cumulative food intake and body weight gain over 14 days. Total fat mass gain, determined by Dual Emission X-ray Absorptiometry, was reduced, while gain in fat-free mass was unchanged. Fasting (5 h) blood glucose was also reduced at the end of the study, with a trend to reduced plasma insulin. Interscapular brown adipose tissue (BAT) weight was reduced, the tissue was noticeably darker in colour and quantitative PCR (TaqMan) analysis of this tissue showed a trend to an increase in uncoupling protein-1 mRNA expression, suggesting that SB-334867-A might stimulate thermogenesis. This was confirmed in a separate study in which a single dose of SB-334867-A (30 mg/kg, i.p.) increased metabolic rate over 4 h in ob/ob mice. OX1 receptor mRNA was detected in BAT, and its expression was increased by 58% by treatment with SB-334867-A. This is the first demonstration that OX1 receptor antagonists have potential as both anti-obesity and anti-diabetic agents.

Introduction

Orexins-A (OXA) and -B (OXB) are C-terminally amidated peptides of 33 and 28 amino acids, respectively, derived from the same precursor peptide [1]. They activate two G-protein-coupled receptors: the orexin-1 (OX1) receptor, which has approximately 10-fold greater affinity for OXA than OXB, and the OX2 receptor, which has similar affinity for the two peptides [2], [3].

Intracerebroventricular (i.c.v.) injection of the orexins, especially of OXA, stimulates feeding, giving rise to their name [1], [4]. However, whether the orexins are physiologically important in the regulation of feeding or in the development of obesity is open to question because in some studies they have had only weak effects on food intake, and obese (fa/fa) Zucker rats have shown no difference in brain OXA or hypothalamic prepro–orexin mRNA levels from lean rats [5], [6], [7]. An alternative role is thought to be in the regulation of sleep and arousal [6], [8]. Other studies, in contrast, have shown reductions in hypothalamic prepro–orexin mRNA levels not only in fa/fa rats, but also in ob/ob and db/db mice [9], [10]. Moreover, there was an elevated level of hypothalamic prepro–orexin mRNA in rats prone to obesity on a high-fat diet that increases further when the rats are administered such a diet [11]. Overall, the evidence for OXA having a role in the regulation of feeding can be compared favourably with that for two other orexigenic peptides, melanin-concentrating hormone and galanin [12], [13]. This does not preclude roles for orexins in the regulation of sleep and other behaviours, or in neurohormonal regulation. Indeed, it seems possible that orexins may mediate a range of responses that support food-seeking behaviour when there is a deficiency of fuel for the brain [13], [14].

A key criterion supporting a role for a neuropeptide in the regulation of feeding is that blockade of its activity should alter natural feeding. This evidence is available for the orexin system since central administration of antibodies to both OXA and the OX1 receptor reduces food intake [15], [16]. In addition, we have shown that SB-334867-A, an OX1 receptor antagonist with 50-fold lower affinity for the OX2 receptor [17], [18], [19], reduces food consumption in male and female rats [20]. The structure of feeding behaviour (the behavioural satiety sequence) is well-preserved: SB-334867-A advanced the transition from feeding to resting in the manner of other satiety agents, and there was no disruption in the behavioural satiety sequence which known sedative agents elicit [21].

We now report that in genetically obese (ob/ob) mice, SB-334867-A not only reduced food intake, but also increased energy expenditure, and on repeated administration, reduced body weight via a reduction in body fat content while preserving lean mass. Furthermore, fasting blood glucose was lowered despite a trend to reduced plasma insulin, indicating increased insulin sensitivity. These findings provide further evidence that orexins play a role in the regulation of energy balance, and suggest that OX1 receptor antagonists have potential in the treatment of obesity and Type 2 diabetes.

Section snippets

Animals

Female ob/ob mice were obtained from Harlan Olac at 6–7 weeks of age. On arrival, they were housed under controlled temperature (24±2 °C) and lighting conditions (12 h light–dark cycle), and were allowed 5 days habituation prior to the study. Food (chow pellets) and water were available ad libitum. All procedures carried out were in accordance with Home Office Guidelines.

Compound preparation and administration

SB-334867-A [17], [18], [19] and the β3-adrenoceptor agonist

Food consumption and body weight

SB-334867-A significantly reduced cumulative 24 h food intakes between days 3 and 14 (last measurement) of the study (Fig. 1). Since SB-334867-A might have a greater effect on food intake in the period immediately following each injection than at later times during each 24 h period, food intake was also measured at 4 h post-dose on three occasions. At 4 h post-dose, SB-334867-A reduced food intake on days 1 (by 33±15%, P=0.06), 6 (by 28±9%, P=0.17) and 13 (by 29±22%, P=0.24); these changes were

Discussion

These findings in ob/ob mice demonstrate an anti-obesity effect with a selective OX1 receptor antagonist for the first time. The inhibitory effects of SB-334867-A on food intake are consistent with our previous work, which was carried out in Sprague Dawley [20] or Lister hooded [21] rats. Cumulative food intake in ob/ob mice was reduced over the entire 14 days of the study, without any signs of desensitisation. SB-334867-A also reduced body weight gain, with the greatest reduction being

References (38)

  • G.B.T. Moore et al.

    Overexpression of UCP-3 in skeletal muscle of mice results in increased expression of mitochondrial thioesterase mRNA

    Biochem. Biophys. Res. Commun.

    (2001)
  • P.C. Even et al.

    Practical aspects of indirect calorimetry in laboratory animals [Review]

    Neurosci. Biobehav. Rev.

    (1994)
  • P.W. Young et al.

    Prolonged β-adrenoceptor stimulation increases the amount of GDP-binding protein in brown adipose tissue mitochondria

    Life Sci.

    (1984)
  • D. Ricquier et al.

    Expression of uncoupling protein mRNA in thermogenic or weakly thermogenic brown adipose tissue

    J. Biol. Chem.

    (1986)
  • J.R. Arch

    The contribution of increased thermogenesis to the effect of anorectic drugs on body composition in mice

    Am. J. Clin. Nutr.

    (1981)
  • M. Lubkin et al.

    Independent feeding and metabolic actions of orexins in mice

    Biochem. Biophys. Res. Commun.

    (1998)
  • Z. Arihara et al.

    Immunoreactive orexin-A in human plasma

    Peptides

    (2001)
  • D. Smart et al.

    Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR

    Br. J. Pharmacol.

    (1999)
  • D. Smart et al.

    The hypocretins are weak agonists at recombinant human orexin-1 and orexin-2 receptors

    Br. J. Pharmacol.

    (2000)
  • Cited by (132)

    • Investigating a role of orexin and ‘cocaine- and amphetamine-regulated transcript’ in the nucleus accumbens shell in binge eating of male rats and the relationship with impulsivity

      2022, Physiology and Behavior
      Citation Excerpt :

      In the BINGE group, the reduction of PF consumption by SB did not reach a significant level, independent of impulsivity (Fig 8A, C), nor did the infusion affect the consumed amount of standard food (chow). The reduction in total and relative PF intake in the control group (Fig 8A, Fig 9A) is in accordance with previous findings, which demonstrated that antagonizing OX1Rs by systemic, i.c.v or intra-NAc(Sh) infusions, significantly decreased chow and PF consumption in sated, fasted and food restricted rats and mice [74–83]. The effect of systemic OX1R blockade to reduce PF intake was independent of satiety state or sex [84].

    • Hypocretin (Orexin): What It Does and How It Links With Narcolepsy and Food Choices

      2020, Neurological Modulation of Sleep: Mechanisms and Function of Sleep Health
    View all citing articles on Scopus
    View full text